Compare AU
Compare RIIF vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are RIIF and DRUG. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.
Community Stats
RIIF | DRUG | |
|---|---|---|
Popularity | N/A | Low |
Pearlers invested | 0 | 64 |
Median incremental investment | $0 | $990.50 |
Median investment frequency | N/A | Monthly |
Median total investment | $0 | $1,963.48 |
Average age group | N/A | 26 - 35 |
Key Summary
RIIF | DRUG | |
|---|---|---|
Strategy | RIIF.AX was created on 2024-08-12 by Resolution Capital. The fund's investment portfolio concentrates primarily on theme equity. The Fund aims to achieve an annual total return that exceeds the total return of the Benchmark after fees on a rolling 3-year basis | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | Resolution Gbl Listed Infra Fund - Active ETF (100 %) | BRL - BRAZILIAN REAL (0 %) AUD - AUSTRALIA DOLLAR (0 %) CHF - SWISS FRANC (0 %) |
Top 3 industries | Other (77.10 %) Communication Services (33.53 %) Health Care (22.75 %) | |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | |
Management fee | 0 % | 0.57 % |
Key Summary
RIIF | DRUG | |
|---|---|---|
Issuer | Resolution Capital | BetaShares |
Tracking index | FTSE Developed Core Infrastructure 50/50 Index - AUD - Benchmark TR Net Hedged | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0 % | 0.57 % |
Price | $1.09 | $7.64 |
Size | N/A | $162.958 million |
10Y return | N/A | N/A |
Annual dividend/ distribution yield (5Y) | 0.17 % | 1.89 % |
Market | ASX | ASX |
First listed date | 24/03/2025 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
RIIF | DRUG | |
|---|---|---|
Popularity | N/A | Low |
Pearlers invested | 0 | 64 |
Median incremental investment | $0 | $990.50 |
Median investment frequency | N/A | Monthly |
Median total investment | $0 | $1,963.48 |
Average age group | N/A | 26 - 35 |
Pros and Cons
RIIF | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
RIIF | DRUG |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Lower distribution yield | Higher distribution yield |